Coral Laboratories Ltd.
Snapshot View

260.70 +17.05 ▲7.0%

20 May 2022, 04:01:00 PM
Volume: 363

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.corallab.com
Market Cap 92.91 Cr.
Enterprise Value(EV) 53.76 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 23.07 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 11.27 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 440.87 Trailing Twelve Months Ending 2021-12
Price to Book Value 0.59 Calculated using Price: 260.05
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.36 Cr. 3,572,600 Shares
FaceValue 10
Company Profile

Coral Laboratories was founded in 1994. The company is equipped with an ultra modern manufacturing unit in the state of Gujarat, Daman & today is a force to reckon with in the pharmaceutical industry; a fact which has been endorsed by the WHO GMP certification issued by the Food & Drugs Control Administration and ISO 9001-2000 Quality certification issued by American Quality Assessors.

The Company with deep basket of products is focused in hostlic human welfare and is bringing planfort to people with its Inflammatory, Bacterial, Biotic, Protein deficiencies & Skin conditions. Medicines across the nation, manufactured under the ZEST group & MOXBRO group being the most popular brands across the nation, manufactured by the company.Coral Laboratories has been following a steady growth path on the pillars of its philosophy of “Total Quality Management” & “Quality Products at Affordable Prices”.

The state-of-the art manufacturing facilities meet the stringent and over changing quality requirement of the most discerning buyers. Coral has a multi location manufacturing facilities based on Baroda, Daman & Vasai for strategies convenience. The facilities carrying WHO-GMP & ISO 9001 : 2000 certification. The new manufacturing facilities under expansion to have UK – MHRA and US– FDA certification.

Coral has one of the best quality control laboratory in indian pharmaceuticals industry equipped with latest and sensitive laboratory instruments.

Product range of the company includes:

  • Capsules & Dry Syrups
  • Tablets
  • Liquid Orals
  • Kits
  • Ointment & Cream
  • Injection – Eye – Ear Drops
  • Others

Achievements/ recognition:

  • WHO GMP certification issued by the Food & Drugs Control Administration
  • ISO 9001-2000 Quality certification issued by American Quality Assessors.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+7.00%
1 Week
+5.46%
1 Month
-6.59%
3 Month
-8.41%
6 Month
-16.20%
1 Year
-36.16%
2 Year
+97.13%
5 Year
-75.65%
10 Year
+290.85%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 14.76 16.72 17.46 19.18 18.17 11.04 8.88 6.22 10.74
Return on Capital Employed (%) 18.70 21.24 22.22 26.93 27.23 15.91 13.44 7.86 13.53
Return on Assets (%) 11.25 13.25 14.40 15.32 14.77 9.17 7.40 5.09 8.69

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 44 51 59 70 109 116 114 116 137 157
Non Curr. Liab. 1 1 1 1 3 4 4 4 3 3
Curr. Liab. 14 9 12 18 19 20 18 25 28 15
Minority Int.
Equity & Liab. 58 61 72 89 131 140 136 144 168 175
Non Curr. Assets 24 23 22 25 58 68 52 48 57 72
Curr. Assets 34 37 50 65 74 72 84 96 111 103
Misc. Exp. not W/O
Total Assets 58 61 72 89 131 140 136 144 168 175

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 42 51 59 77 95 92 91 71 97 83
Other Income 1 1 3 3 3 4 5 6 4 5
Total Income 43 52 62 80 99 97 96 76 100 89
Total Expenditure -34 -41 -47 -61 -72 -77 -79 -65 -80 -74
PBIDT 9 11 15 19 27 20 18 11 20 15
Interest 0 0 0 0 0 0 0 0 0 -1
Depreciation -1 -1 -3 -2 -2 -2 -2 -2 -2 -2
Taxation -2 -2 -3 -5 -8 -6 -5 -2 -4 -4
Exceptional Items 0 0 0
PAT 6 8 10 12 16 12 10 7 14 8
Adjusted EPS 17 22 27 35 46 35 29 20 38 23

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 3 0 1 0 5 11 13 -1 -4 1
Cash Fr. Inv. 0 0 1 0 -3 -10 -13 3 -2 0
Cash Fr. Finan. 0 0 0 0 0 0 -3 -1 4 0
Net Change 3 1 2 0 2 1 -2 1 -2 1
Cash & Cash Eqvt 4 5 7 7 9 4 2 3 1 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 71.51 71.51 71.51 71.51 71.51 71.51 71.51 71.51 71.51
Public 28.49 28.49 28.49 28.49 28.49 28.49 28.49 28.49 28.49
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Board Meeting Intimation for Notice Under Regulation 29(1) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
CORAL LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve 1.Standalone Audited Financial Results for the Quarter and Financial Year Ended March 31 2022.2. Appointment of Secretarial Auditor.3.Any other business with the permission of chairman.
Tue, 19 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayCORAL LABORATORIES LTD.
2CINL24231GJ1997PLC031669
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Ruchi Anjaria
Designation: Company Secretary and Compliance Officer
EmailId: cs@corallab.com
Name of the Chief Financial Officer: Sushma Kadkade
Designation: Director and CFO
EmailId: accounts@corallab.com

Date: 19/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Fri, 15 Apr 2022
Compliance Certificate From PCS As Per Regulation 40(9) And 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
As per the requirement of the Regulation 40(9) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith Original Certificate from practicing Company Secretaries M/s SARK & Associates in compliance with requirement under Regulation 40(10) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended March 31 2022.

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Making Lower Lows for 3 days Making Lower Lows for 3 days
Close Within 52 Week Low Zone Close Within 52 Week Low Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%